1. Home
  2. TBPH vs MBUU Comparison

TBPH vs MBUU Comparison

Compare TBPH & MBUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • MBUU
  • Stock Information
  • Founded
  • TBPH 2013
  • MBUU 1982
  • Country
  • TBPH United States
  • MBUU United States
  • Employees
  • TBPH N/A
  • MBUU N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • MBUU Marine Transportation
  • Sector
  • TBPH Health Care
  • MBUU Industrials
  • Exchange
  • TBPH Nasdaq
  • MBUU Nasdaq
  • Market Cap
  • TBPH 699.0M
  • MBUU 633.5M
  • IPO Year
  • TBPH N/A
  • MBUU 2014
  • Fundamental
  • Price
  • TBPH $14.26
  • MBUU $30.25
  • Analyst Decision
  • TBPH Strong Buy
  • MBUU Hold
  • Analyst Count
  • TBPH 4
  • MBUU 6
  • Target Price
  • TBPH $23.00
  • MBUU $33.60
  • AVG Volume (30 Days)
  • TBPH 301.7K
  • MBUU 172.4K
  • Earning Date
  • TBPH 11-11-2025
  • MBUU 10-30-2025
  • Dividend Yield
  • TBPH N/A
  • MBUU N/A
  • EPS Growth
  • TBPH N/A
  • MBUU N/A
  • EPS
  • TBPH 0.26
  • MBUU 0.76
  • Revenue
  • TBPH $77,205,000.00
  • MBUU $807,561,000.00
  • Revenue This Year
  • TBPH $79.82
  • MBUU N/A
  • Revenue Next Year
  • TBPH N/A
  • MBUU $8.01
  • P/E Ratio
  • TBPH $54.87
  • MBUU $40.03
  • Revenue Growth
  • TBPH 24.49
  • MBUU N/A
  • 52 Week Low
  • TBPH $7.90
  • MBUU $24.43
  • 52 Week High
  • TBPH $15.15
  • MBUU $47.82
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 54.96
  • MBUU 41.35
  • Support Level
  • TBPH $13.50
  • MBUU $28.40
  • Resistance Level
  • TBPH $14.59
  • MBUU $31.06
  • Average True Range (ATR)
  • TBPH 0.50
  • MBUU 1.05
  • MACD
  • TBPH -0.09
  • MBUU -0.01
  • Stochastic Oscillator
  • TBPH 46.31
  • MBUU 35.85

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MBUU Malibu Boats Inc.

Malibu Boats is a leading designer and manufacturer of power boats in the United States. It is a top manufacturer of performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a leading producer of sterndrive boats in the US in the 24- to 29-foot segment, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a top seller of flat fishing boats, including bay, dual-console, and center-console boats. Malibu has also expanded into boat trailers and accessories, and in 2020 began producing its own engines (Monsoon) for its performance sport boats and now for Cobalt. Malibu's target market includes a wide range of water enthusiasts who embrace the active outdoor lifestyle.

Share on Social Networks: